I feel worse: is it my ABPA or Asthma?

Deciding which is causing a symptom change is one of the biggest challenges in managing ABPA and asthma together, since the two conditions often overlap and interact.

Here’s a breakdown to help you tell which condition might be driving your symptoms — though in many cases, they contribute together:

🧭 ABPA vs Asthma: Symptom Clues

Symptom	More Likely ABPA	More Likely Asthma
Increased sputum / mucus plugging	✅ Thick, sticky, brownish mucus common in ABPA	❌ Asthma usually has dry cough, not much mucus
Sudden worsening after steroid reduction	✅ Flare of ABPA likely	❌ Asthma usually responds to inhalers unless severe
Persistent wheeze despite good inhaler use	✅ Could suggest ABPA inflammation or mucus	✅ Asthma too, but should improve with bronchodilators
Raised total IgE or eosinophils	✅ Strong ABPA clue	✅ Can happen in asthma too, but less extreme
Fever, malaise, or feeling ‘infected’	✅ Possible in ABPA flares	❌ Not typical in asthma
Crackles or signs on chest exam	✅ More common in ABPA with bronchiectasis	❌ Asthma usually has wheeze, not crackles
Daily productive cough	✅ Common in ABPA and bronchiectasis	❌ Asthma usually has dry, episodic cough

🧪 How Doctors Distinguish Them

Blood tests: Total IgE, eosinophils, Aspergillus-specific IgE
Sputum cultures: To check for Aspergillus or secondary infection
Spirometry: Looks for reversible airflow obstruction (asthma)
Chest CT scan: Shows mucus plugging, central bronchiectasis (ABPA)
Steroid response test: Asthma often improves rapidly; ABPA needs longer or higher doses

🔄 Important: They Often Coexist

Many people with ABPA have asthma first.
ABPA may worsen asthma symptoms by causing inflammation, mucus plugging, and airway damage.
Treating ABPA (with steroids, antifungals, or omalizumab) often improves asthma control.

✅ What You Can Do

Keep a symptom diary: track mucus, breathlessness, triggers, and response to inhalers or steroids.
Ask your care team to help you track your IgE and eosinophils over time.
If you’re on biologics (e.g., omalizumab), monitor exacerbation frequency and inhaler needs.